Sentences with phrase «lymphoblastic leukemia patients»

Study finds age, ancestry and genetics can influence the risk of pancreatitis, a serious chemo side effect in acute lymphoblastic leukemia patients.

Relapsed or refractory chronic lymphocytic leukemia and acute lymphoblastic leukemia patients have shown durable responses of almost 2 years to a novel T - cell engineering technique developed at the University of Pennsylvania Perelman School of Medicine in Philadelphia.

«Personalized cellular therapy achieves complete remission in 90 percent of acute lymphoblastic leukemia patients studied.»

Not exact matches

Juno Therapeutics will resume its Phase II ROCKET clinical trial of its acute lymphoblastic leukemia candidate JCAR015 following the FDA's lifting of a partial clinical hold imposed last week following the deaths of three patients.

JCAR015 is a CD19 - directed chimeric antigen receptor technology (CAR - T) product candidate that has been under study in ROCKET in adult patients with relapsed or refractory B - cell acute lymphoblastic leukemia.

The drug, which was first approved last August for patients under 25 with B - cell precursor acute lymphoblastic leukemia, is now OK» ed to treat large B - cell lymphoma.

For the second time in 5 months, Juno Therapeutics has put a clinical hold on a Phase II trial of JCAR015 in adult patients with relapsed or refractory B - cell acute lymphoblastic leukemia due to patient deaths.

Juno Therapeutics is seeking to change the protocol for the Phase II ROCKET clinical trial of its acute lymphoblastic leukemia candidate JCAR015, which the FDA has placed on clinical hold following the deaths of three patients, two of them last week.

After seeing promising results in phase 1 of the Pediatric Leukemia Adoptive Therapy (PLAT - 02) trial with 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50 Leukemia Adoptive Therapy (PLAT - 02) trial with 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50 leukemia (ALL) achieving complete initial remission, researchers at Seattle Children's are continuing their quest to improve the experimental therapy and reduce the rate of relapse, which is about 50 percent.

Wednesday's FDA advisory panel took no issue with CTL019's positive effects on patients with acute lymphoblastic leukemia that has persisted despite prior treatment.

Noelle Frey, MD, an assistant professor of Hematology - Oncology, will present results in 27 adult patients with acute lymphoblastic leukemia (ALL), identifying an optimal dose and infusion regimen that should improve treatment response while reducing potential for side effects.

His group was the first to publish findings of dramatic molecular remissions in patients with chemorefractory acute lymphoblastic leukemia following treatment with autologous CD19 - targeted T cells.

Herbert OettgenCRI CONNECTIONCVC MEMBERSCIENTIFIC ADVISOR reports the first treatment of patients with acute lymphoblastic leukemia with L - asparaginase.

The FDA granted approval to a new, first - in - class immunotherapy — tisagenlecleucel (Kymriah, Novartis)-- for the treatment patients up to 25 years old with B cell acute lymphoblastic leukemia (B - ALL) that is refractory or has relapsed after at least two previous treatments.

The patient was treated on an acute lymphoblastic leukemia (ALL) protocol for eight cycles of hyperCVAD (cyclophosphamide, vincristine, adriamycin and decadron) alternating with MTX / Ara - C (methotrexate and cytarabine) and achieved complete remission (CR) confirmed by a bone marrow biopsy and by the resolution of most of her skin lesions.

The use of minimal residual disease (MRD) provided a more objective measure of induction failure in patients with pediatric acute lymphoblastic leukemia (ALL) than did morphology, according to the results of a study published recently in the Journal of Clinical Oncology.

Endari, the first new treatment for patients with sickle cell disease in almost 20 years, Genentech's Hemlibra, the first - ever non-blood product to treat patients with hemophilia A with inhibitors, Actemra, the first treatment for adults diagnosed with giant cell arteritis, BioMarin's Brineura, the first treatment for a form of Batten disease, Benznidazole, the first U.S. treatment for Chagas disease, Novartis» Kymriah to treat certain children and young adults with B - cell acute lymphoblastic leukemia, which is also the first gene therapy to become available in the United States, are some of the drugs that received the FDA's stamp of approval in 2017.

Building on proof - of - principle experimentation in mice bearing CD19 + malignancies, the MSKCC team led by Dr. Sadelain has recently obtained dramatic clinical responses in adult patients with acute lymphoblastic leukemia.

Whole genome and whole transcriptome sequencing of 31 pediatric Asian patients with T - cell acute lymphoblastic leukemia found that about 10 percent had the same alteration in a non-coding region of DNA.

In 2005, the identification of an activating mutation in JAK2 (the V617F mutation) as a STAT5 - activating and disease - causing genetic alteration in a significant proportion of patients with myeloproliferative neoplasms (MPNs) has emphasized the oncogenic role of the JAK tyrosine kinases in hematologic malignancies.2 — 5 JAK2 is a member of the Janus tyrosine kinase family comprising three other mammalian non-receptor tyrosine kinases (JAK1, JAK3 and TYK2) that associate with cytokine receptors lacking intrinsic kinase activity to mediate cytokine - induced signal transduction and activation of STAT transcription factors.6 All JAKs share a similar protein structure and contain a tyrosine kinase domain at the C - terminus flanked by a catalytically inactive pseudokinase domain with kinase - regulatory activity, by an atypical SH2 domain and by a FERM domain that mediates association to the membrane - proximal region of the cytokine receptors.7, 8 Soon after the discovery of JAK2 V617F, we and others described that activating JAK1 mutations are relatively common in adult patients with T - cell acute lymphoblastic leukemia (ALL) and participate in ALL development allowing for constitutive activation of STAT5.9 — 11 Several STAT5 - activating JAK1 mutations were also reported in AML and breast cancer patients.10

In a patient with relapsed B - cell acute lymphoblastic leukemia, a single dose of 5 × 10 (4) / kg 1928zT2 T cells resulted in robust expansion and leukemia eradication and led to complete remission.

«The data show that aberrant epigenetic gene programming can now be considered a hallmark of acute lymphoblastic leukemia, occurring in all patients regardless of the presence of genetic mutations,» Melnick said.

The new results — from trials for patients with advanced lymphoma, multiple myeloma, and pancreatic cancer — expand on Penn's work with chimeric antigen receptor (CAR) therapies, building on findings in patients with chronic lymphocytic leukemia and acute lymphoblastic leukemia dating back to the start of the first clinical trial in 2010.

The patient population for the pilot will be children aged 3 through 11 years who are newly diagnosed with acute lymphoblastic leukemia — the most commonly - diagnosed childhood cancer — or who have been in treatment for less than 12 months.

The 101 medical malpractice lawsuits reportedly arose in 1998 after university hospital officials disclosed that many pediatric oncology patients were likely not provided with the newest or most effective treatment for acute lymphoblastic leukemia during a seven - year period.

I am now testing patients with ALL (Acute Lymphoblastic Leukemia), using R...